Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Primary analysis of Pola-G-Len: favorable findings for R/R follicular lymphoma

Catherine Diefenbach • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Obinutuzumab Polatuzumab vedotin
GO29834

Catherine Diefenbach, MD, Perlmutter Cancer Center at NYU Langone Health, New York, NY, presents the primary analysis of polatuzumab plus obinutuzumab and lenalidomide for heavily-pretreated relapsed/refractory follicular lymphoma (GO29834; NCT02600897). This novel triplet combination showed a safety profile similar to the individual drugs and high complete response rates at the end of induction, supporting further investigation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Catherine Diefenbach

6:45
Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT
Catherine Diefenbach • 11 Dec 2023
1:34
How will bispecifics impact the treatment of NHL?
Catherine Diefenbach • 11 Dec 2022
2:31
Long-term follow up of study of obinutuzumab, polatuzumab vedotin, and lenalidomide in R/R FL
Catherine Diefenbach • 11 Dec 2022
1:30
Advances in the management of R/R Hodgkin lymphoma
Catherine Diefenbach • 11 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals